Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) gapped up prior to trading on Tuesday after an insider bought additional shares in the company. The stock had previously closed at $14.01, but opened at $14.94. Astria Therapeutics shares last traded at $14.33, with a volume of 175,761 shares. Specifically, Director Perceptive Advisors Llc […]
Wedbush reissued their outperform rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research note published on Tuesday, Benzinga reports. The firm currently has a $17.00 price target on the biotechnology company’s stock. A number of other analysts also recently weighed in on ATXS. HC Wainwright reduced their target price on shares […]
Wedbush restated their outperform rating on shares of Astria Therapeutics (NASDAQ:ATXS – Free Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm currently has a $17.00 price objective on the biotechnology company’s stock. ATXS has been the subject of several other research reports. Oppenheimer decreased their target price on […]
Astria Therapeutics, Inc. (NASDAQ:ATXS – Get Free Report) Director Perceptive Advisors Llc purchased 1,074,608 shares of Astria Therapeutics stock in a transaction dated Monday, October 16th. The shares were purchased at an average price of $6.51 per share, for a total transaction of $6,995,698.08. Following the completion of the acquisition, the director now owns 1,652,371 […]
By Ben Glickman Astria Therapeutics entered a global exclusive license agreement with Ichnos Sciences for an OX40 portfolio to be developed for the potential.